03 December 2025
EMA/CAT/380010/2025
Human Medicines Division

Committee for Advanced Therapies (CAT)

Draft agenda for the meeting on 03-05 December 2025

Chair: Ilona Reischl; Vice-Chair: Kieran Breen

03 December 2025, 14:00 – 18:30

04 December 2025, 09:00 – 18:30

05 December 2025, 09:00 – 13:00

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CAT plenary session to be held 03-05 December 2025. See December 2025 CAT minutes (to be published post January 2026 CAT meeting).

1.2. Adoption of agenda

CAT agenda for 03-05 December 2025 meeting

1.3. Adoption of the minutes

CAT minutes for 05-07 November 2025 meeting

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

2.3.1. Nadofaragene firadenovec - EMEA/H/C/005856

Treatment of adult patients with high-grade (HG), Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).

Scope: Day 180 list of outstanding issues

Action: for adoption

List of questions adopted on 16.04.2025.

2.4. Day 120 list of questions

No items

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

No items

2.7. New applications

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

2.9.1. JELRIX - Autologous cartilage-derived articular chondrocytes, in-vitro expanded - EMEA/H/C/004594

TETEC Tissue Engineering Technologies AG; repair of symptomatic, localised, full-thickness cartilage defects of the knee joint grade III or IV

Scope: Withdrawal of the marketing authorisation application

Action: for information

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/VR/0000302440

Janssen Cilag International

Rapporteur: Jan Mueller-Berghaus

Scope: Quality, opinion

Action: for adoption

2.11.2. Ebvallo - Tabelecleucel - Orphan - EMA/VR/0000284818

Pierre Fabre Medicament

Rapporteur: Egbert Flory

Scope: Quality, opinion

Action: for adoption

2.11.3. Kymriah - Tisagenlecleucel - Orphan - EMA/VR/0000302038

Novartis Europharm Limited

Rapporteur: Rune Kjeken

Scope: Quality, request for supplementary information

Action: for adoption

2.11.4. Yescarta - Axicabtagene ciloleucel - Orphan - EMA/VR/0000301490

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Karin Erneholm

Scope: Clinical, opinion

Submission of the final report from study KTE-C19-105 (ZUMA-5) to fulfil additional pharmacovigilance activities (Category 3) requirements listed in RMP. This is a phase 2 multicenter study of axicabtagene ciloleucel in subjects with relapsed/refractory indolent non-Hodgkin lymphoma. The RMP version 11.3 has also been submitted.

Action: for adoption

2.11.5. Yescarta - Axicabtagene ciloleucel - Orphan - EMA/VR/0000280312

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus

Scope: Quality, opinion

Action: for adoption

2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

2.13.1. Aucatzyl - Obecabtagene autoleucel - Orphan - EMA/PAM/0000301546

Autolus GmbH

Rapporteur: Tineke van den Hoorn, PRAC Rapporteur: Karin Erneholm

Scope: PAM, opinion

Action: for adoption

2.13.2. Aucatzyl - Obecabtagene autoleucel - Orphan - EMA/PASS/0000300590

Autolus GmbH

Rapporteur: Tineke van den Hoorn, PRAC Rapporteur: Karin Erneholm

Scope: Imposed PASS protocol

Action: for information

2.13.3. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/PAM/0000301551

Janssen Cilag International

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Jo Robays

Scope: PAM, PRAC led

Action: for adoption

2.13.4. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/PAM/0000304040

Janssen Cilag International

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Jo Robays

Scope: PAM

Action: for adoption

2.13.5. Hemgenix - Etranacogene dezaparvovec - Orphan - EMA/PAM/0000302041

CSL Behring GmbH

Rapporteur: Silke Dorner

Scope: PAM, opinion

Action: for adoption

2.13.6. Tecartus - Brexucabtagene autoleucel - Orphan - EMA/PAM/0000267756

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Bianca Mulder

Scope: PAM

Action: for adoption

2.13.7. Casgevy - Exagamglogene autotemcel - Orphan - EMA/R/0000290395

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Bianca Mulder

Scope: Renewal - 1 year, opinion

Action: for adoption

2.13.8. Strimvelis - Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - Orphan - EMA/R/0000290462

Fondazione Telethon Ets

Rapporteur: Sol Ruiz, Co-Rapporteur: Egbert Flory, PRAC Rapporteur: Liana Martirosyan

Scope: Renewal - 5 year

Action: for adoption

2.13.9. Upstaza - Eladocagene exuparvovec - Orphan - EMA/S/0000293355

PTC Therapeutics International Limited

Rapporteur: Joseph De Courcey, PRAC Rapporteur: Dirk Mentzer

Scope: Annual reassessment

Action: for adoption

2.13.10. Reporting of out of specification ATMP

Scope: Proposal for a new approach

Action: for adoption

2.14. Companion diagnostics - initial consultation

No items

2.15. Companion diagnostics – Follow-up consultation

No items

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

No items

4. Scientific Recommendation on Classification of ATMPs

Timetable:

-Start of the procedure:	22.12.2025
-EMA Coordinator's draft report:	16.12.2025
-CAT Coordinator's comments:	19.12.2025
-Revised scientific recommendation:	14.01.2026
-CAT's discussion of scientific recommendation:	16.01.2026

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Red blood cells derived from immortalised hematopoietic progenitors

Blood transfusion

Scope: for nomination of CAT coordinator

Action: for adoption

4.1.2. Platelets derived from immortalised hematopoietic progenitors

Platelet transfusion

Scope: for nomination of CAT coordinator

Action: for adoption

4.1.3. Allogeneic human induced pluripotent stem cell (hiPSC)-derived midbrain dopaminergic (mDA) neuronal progenitor cells

Treatment of Parkinson's disease

Scope: for nomination of CAT coordinator

Action: for adoption

4.2. Day 30 ATMP scientific recommendation

No items

4.3. Day 60 revised scientific recommendation (following list of questions)

No items

4.4. Finalisation of procedure

4.4.1. Attenuated Salmonella typhi strain Ty21a carrying plasmid pNECVAX-NEO1

Treatment of solid malignancies with or without metastases

Scope: ATMP scientific recommendation. European Commission raised no comments.

Action: for adoption

4.4.2. iPSC-derived Retinal Pigment Epithelium (RPE) cells on a synthetic polymer membrane

Restoring vision in advanced (late-stage) retinitis pigmentosa (RP)

Scope: ATMP scientific recommendation. European Commission raised no comments.

Action: for adoption

4.5. Follow-up and guidance

No items

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests - appointment of CAT Rapporteurs

5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

Timetable:

- Start of procedure at SAWP:	24-27.11.2025
- Appointment of CAT Peer Reviewers:	03-05.12.2025
- SAWP first reports:	05.01.2026
- CAT Peer Reviewer comments (NC & C):	09.01.2026
- CAT Peer Reviewer comments (Q):	14.01.2026
- Discussion at SAWP:	12-15.01.2026
- Discussion at CAT and feedback to SAWP:	21-23.01.2026

5.1.2. Scientific advice procedures starting at the next SAWP meeting

Timetable:

- Start of procedure at SAWP:	12-15.01.2026
- Appointment of CAT Peer Reviewers:	21-23.01.2026
- SAWP first reports:	02.06.2026
- CAT Peer Reviewer comments (NC & C):	06.02.2026
- CAT Peer Reviewer comments (Q):	11.02.2026
- Discussion at SAWP:	09-12.02.2026
- Discussion at CAT and feedback to SAWP:	18-20.02.2026

5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

5.4. Final Advice Letters for procedures finalised the previous month

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment:	
Procedure start:	24-27.11.2025
SAWP recommendation:	15.01.2026
CAT recommendation:	23.01.2026
CHMP adoption of report and final recommendation:	29.01.2026

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

Action: for information

7.1.2. Vote by proxy

Action: for information

7.1.3. CAT Strategic Review & Learning meeting (SRLM) under the Cypriot presidency

Scope: Preparation for the meeting

CAT: Rafaella Pontou

Action: for information

7.2. Coordination with EMA Scientific Committees

No items

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

No items

7.4. Cooperation with the EU regulatory network

7.4.1. EU Life Science Strategy and Biotech Act

European Commission:

Scope: Update to the Committee

Action: for information

7.5. Cooperation with international regulators

7.5.1. ICH Cell and Gene Therapy discussion group

Scope: Update

CAT: Jan Muller-Berghaus

Action: for information

7.5.2. Individualized Therapies on the RISE meeting, FDA

CAT: Ilona Reischl

Scope: Brief summary of the meeting

Action: for information

7.5.3. IPRP (International Pharmaceutical Regulators Programme) cell and gene therapy working group

CAT: Pille Saalik

Scope: Feedback from the IPRP meeting of 13.11.2025

Action: for discussion

7.6. CAT work plan

7.6.1. CAT Workplan 2026

Scope: Work plan topics for 2026

CAT: Ilona Reischl

Action: for discussion

7.6.2. Good Pharmacovigilance Practice (GVP) Module 5

Scope: Update on revision of GVP Module 5 to incorporate ATMP specific feedback

CAT: Olga Kholmanskikh

Action: for discussion

7.7. Planning and reporting

No items

7.8. Others

7.8.1. EMA Lunchtime Talk: Where do we stand in our fight against AMR?

Scope: Agenda of the lunchtime talk organised for CVMP and CAT members on Wednesday 3 December at 13.00

Action: for information

Proposed Agenda:

13.00 - 13.20 - Presentation from Kristina Nadrah, Slovenian CHMP member and specialist in infectious diseases

13.20 - 13.40 - Presentation from Jaap Wagenaar, Professor at the University of Utrecht, main topics of his research are on antimicrobial resistance and on Campylobacter

13.40 - 14.00 - Question time

8. Any other business

No items

Date of next CAT meeting:

21-23 January 2026

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations in Committee CMD documents and in relation to EMA regulatory activities

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists Post-authorisation activities (section 2.11-2.13) and any ATMP related inspection requests (section 2.14).

New applications (sections 2.1. to 2.9.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.4) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures** (section 2.3). Section 2.6 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

New applications (section 2.7.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

Withdrawal of applications (section 2.8.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.9.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Companion diagnostics (section 2.10)

This section lists applications for initial and follow-on consultation of companion diagnostics.

Post-authorisation activities (section 2.11-2.13.)

Section 2.11 lists type II variations, including extension of indication applications and re-examination procedures for type II variations for which the applicant has requested re-examination of the opinion previously issued by the CHMP. Section 2.12 list extension application according to Annex I of Reg. 1234/2008 and section 2.13 includes all other post-authorisation activities concerning authorised ATMPs that are not covered elsewhere in the agenda such as post-authorisation measures, annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

GMP and GCP Inspections Issues (section 2.14.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/